Skip to content

Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina

Research output: Contribution to journalArticle

Standard

Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina. / Bell, Oliver H; Carreño, Ester; Williams, Emily L; Wu, Jiahui; Copland, David A; Bora, Monalisa; Kobayter, Lina; Fruttiger, Marcus; Sim, Dawn A; Lee, Richard W J; Dick, Andrew David; Chu, Colin J.

In: PLoS ONE, 14.02.2020.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{543a2f028e5f4042b89f66dcfe5eaf3e,
title = "Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina",
abstract = "It is not currently possible to reliably visualise and track immune cells in the human central nervous system or eye. Previous work demonstrated that indocyanine green (ICG) dye could label immune cells and be imaged after a delay during disease in the mouse retina. We report a pilot study investigating if ICG can similarly label immune cells within the human retina. Twelve adult participants receiving ICG angiography as part of routine standard of care were recruited. Baseline retinal images were obtained prior to ICG administration then repeated over a period ranging from 2 hours to 9 days. Matched peripheral blood samples were obtained to examine systemic immune cell labelling and activation from ICG by flow cytometry with human macrophage cultures as positive controls. Differences between the delayed near infrared ICG imaging and 488 nm autofluorescence was observed across pathologies, likely arising from the retinal pigment epithelium (RPE). Only one subject demonstrated ICG signal on peripheral blood myeloid cells and only three distinct cell-sized signals appeared over time within the retina of three participants. No significant increase in immune cell activation markers were detected after ICG administration. ICG accumulated in the endosomes of macrophage cultures and was detectable above a minimum concentration, suggesting cell labelling is possible. ICG can label RPE and may be used as an additional biomarker for RPE health across a range of retinal disorders. Standard clinical doses of intravenous ICG do not lead to robust immune cell labelling in human blood or retina and further optimisation in dose and route are required.",
author = "Bell, {Oliver H} and Ester Carre{\~n}o and Williams, {Emily L} and Jiahui Wu and Copland, {David A} and Monalisa Bora and Lina Kobayter and Marcus Fruttiger and Sim, {Dawn A} and Lee, {Richard W J} and Dick, {Andrew David} and Chu, {Colin J}",
year = "2020",
month = "2",
day = "14",
language = "English",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",

}

RIS - suitable for import to EndNote

TY - JOUR

T1 - Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina

AU - Bell, Oliver H

AU - Carreño, Ester

AU - Williams, Emily L

AU - Wu, Jiahui

AU - Copland, David A

AU - Bora, Monalisa

AU - Kobayter, Lina

AU - Fruttiger, Marcus

AU - Sim, Dawn A

AU - Lee, Richard W J

AU - Dick, Andrew David

AU - Chu, Colin J

PY - 2020/2/14

Y1 - 2020/2/14

N2 - It is not currently possible to reliably visualise and track immune cells in the human central nervous system or eye. Previous work demonstrated that indocyanine green (ICG) dye could label immune cells and be imaged after a delay during disease in the mouse retina. We report a pilot study investigating if ICG can similarly label immune cells within the human retina. Twelve adult participants receiving ICG angiography as part of routine standard of care were recruited. Baseline retinal images were obtained prior to ICG administration then repeated over a period ranging from 2 hours to 9 days. Matched peripheral blood samples were obtained to examine systemic immune cell labelling and activation from ICG by flow cytometry with human macrophage cultures as positive controls. Differences between the delayed near infrared ICG imaging and 488 nm autofluorescence was observed across pathologies, likely arising from the retinal pigment epithelium (RPE). Only one subject demonstrated ICG signal on peripheral blood myeloid cells and only three distinct cell-sized signals appeared over time within the retina of three participants. No significant increase in immune cell activation markers were detected after ICG administration. ICG accumulated in the endosomes of macrophage cultures and was detectable above a minimum concentration, suggesting cell labelling is possible. ICG can label RPE and may be used as an additional biomarker for RPE health across a range of retinal disorders. Standard clinical doses of intravenous ICG do not lead to robust immune cell labelling in human blood or retina and further optimisation in dose and route are required.

AB - It is not currently possible to reliably visualise and track immune cells in the human central nervous system or eye. Previous work demonstrated that indocyanine green (ICG) dye could label immune cells and be imaged after a delay during disease in the mouse retina. We report a pilot study investigating if ICG can similarly label immune cells within the human retina. Twelve adult participants receiving ICG angiography as part of routine standard of care were recruited. Baseline retinal images were obtained prior to ICG administration then repeated over a period ranging from 2 hours to 9 days. Matched peripheral blood samples were obtained to examine systemic immune cell labelling and activation from ICG by flow cytometry with human macrophage cultures as positive controls. Differences between the delayed near infrared ICG imaging and 488 nm autofluorescence was observed across pathologies, likely arising from the retinal pigment epithelium (RPE). Only one subject demonstrated ICG signal on peripheral blood myeloid cells and only three distinct cell-sized signals appeared over time within the retina of three participants. No significant increase in immune cell activation markers were detected after ICG administration. ICG accumulated in the endosomes of macrophage cultures and was detectable above a minimum concentration, suggesting cell labelling is possible. ICG can label RPE and may be used as an additional biomarker for RPE health across a range of retinal disorders. Standard clinical doses of intravenous ICG do not lead to robust immune cell labelling in human blood or retina and further optimisation in dose and route are required.

M3 - Article

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

ER -